标题
Emerging drugs for treatment of focal segmental glomerulosclerosis
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume -, Issue -, Pages 1-9
出版商
Informa UK Limited
发表日期
2020-07-30
DOI
10.1080/14728214.2020.1803276
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Understanding the Rewards of Successful Drug Development — Thinking Inside the Box
- (2020) Dhruv Khullar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
- (2020) Michael Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis
- (2020) Yan-Cheng Chao et al. Contemporary Clinical Trials
- Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
- (2020) Christopher S. Wilcox HYPERTENSION
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- The costs and benefits of pharmaceutical innovation: evidence from recent literature
- (2019) Roger Lee Mendoza JOURNAL OF MEDICAL ECONOMICS
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
- (2019) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Adaptive platform trials: definition, design, conduct and reporting considerations
- (2019) NATURE REVIEWS DRUG DISCOVERY
- Human kidney organoids: progress and remaining challenges
- (2019) Ryuichi Nishinakamura Nature Reviews Nephrology
- Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes
- (2019) Eugene Yu-hin Chan et al. KIDNEY INTERNATIONAL
- Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases
- (2019) Marie Ito et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
- (2018) Md Abdul Hye Khan et al. DIABETOLOGIA
- Bardoxolone—the Phoenix?
- (2018) Robert D. Toto JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Should We Increase GFR with Bardoxolone in Alport Syndrome?
- (2018) Colin Baigent et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- ASK1 contributes to fibrosis and dysfunction in models of kidney disease
- (2018) John T. Liles et al. JOURNAL OF CLINICAL INVESTIGATION
- JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis
- (2018) Jianling Tao et al. KIDNEY INTERNATIONAL
- An update on LDL apheresis for nephrotic syndrome
- (2018) Rupesh Raina et al. PEDIATRIC NEPHROLOGY
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
- (2018) Howard Trachtman et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis
- (2018) Alla Mitrofanova et al. KIDNEY INTERNATIONAL
- Sequential Multiple Assignment Randomized Trials: An Opportunity for Improved Design of Stroke Reperfusion Trials
- (2017) William J. Meurer et al. Journal of Stroke & Cerebrovascular Diseases
- FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
- (2017) Xiaoxin X. Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Rac1 activation in podocytes induces the spectrum of nephrotic syndrome
- (2017) Richard Robins et al. KIDNEY INTERNATIONAL
- Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
- (2017) Colin Baigent et al. KIDNEY INTERNATIONAL
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- (2017) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
- (2017) Kazumoto Iijima et al. PEDIATRIC NEPHROLOGY
- A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models
- (2017) Yiming Zhou et al. SCIENCE
- Sequential Multiple Assignment Randomized Trials: An Opportunity for Improved Design of Stroke Reperfusion Trials
- (2017) William J. Meurer et al. Journal of Stroke & Cerebrovascular Diseases
- Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease
- (2016) Radko Komers et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology
- (2016) L. H. Mariani et al. Clinical Journal of the American Society of Nephrology
- Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury
- (2016) Christopher E. Pedigo et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
- (2016) James Voelker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Clinical Trials in FSGS: Past Challenges and New Trial Designs
- (2016) Deb Gipson SEMINARS IN NEPHROLOGY
- Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models
- (2015) Mario Schiffer et al. NATURE MEDICINE
- Complement Activation in Patients with Focal Segmental Glomerulosclerosis
- (2015) Joshua M. Thurman et al. PLoS One
- The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
- (2015) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- The Treatment of Idiopathic Focal Segmental Glomerulosclerosis in Adults
- (2014) Jonathan Hogan et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Mechanisms of Disease Reversal in Focal and Segmental Glomerulosclerosis
- (2014) Hai-Chun Yang et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Treatment of FSGS in Children
- (2014) Christine B. Sethna et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
- (2014) Melanie P. Chin et al. AMERICAN JOURNAL OF NEPHROLOGY
- Keap1 inhibition attenuates glomerulosclerosis
- (2014) Yoichi Miyazaki et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abatacept in B7-1–Positive Proteinuric Kidney Disease
- (2013) Chih-Chuan Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms and Treatment of CKD
- (2012) P. Ruggenenti et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Focal Segmental Glomerulosclerosis and Chronic Kidney Disease in Pediatric Patients
- (2011) Jeremy Kiffel et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
- (2011) Howard Trachtman et al. KIDNEY INTERNATIONAL
- Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
- (2011) Changli Wei et al. NATURE MEDICINE
- Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis
- (2011) A. Fornoni et al. Science Translational Medicine
- Effects of p38 mitogen-activated protein kinase inhibition on anti-neutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo
- (2010) B. S. van der Veen et al. ANNALS OF THE RHEUMATIC DISEASES
- Activation of NFAT Signaling in Podocytes Causes Glomerulosclerosis
- (2010) Y. Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group
- (2009) Melanie S. Joy et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Phase I Trial of Rosiglitazone in FSGS: I. Report of the FONT Study Group
- (2008) M. S. Joy et al. Clinical Journal of the American Society of Nephrology
- The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
- (2008) Christian Faul et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now